Search results
Results from the WOW.Com Content Network
SEER collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 34.6% of the population of the United States. SEER coverage includes 30.0% of African Americans, 44% of Hispanics, 49.3% of American Indians and Alaska Natives, 57.5% of Asians, and 68.5% of Hawaiian/Pacific Islanders. [3]
In 2008, cancer was responsible for about 25% of all US deaths. The statistics below are estimates for the U.S. in 2008, and may vary substantially in other countries. They exclude basal and squamous cell skin cancers, and carcinoma in situ in locations other than the urinary bladder. [20]
In the United States during 2013–2017, the age-adjusted mortality rate for all types of cancer was 189.5/100,000 for males, and 135.7/100,000 for females. [1] Below is an incomplete list of age-adjusted mortality rates for different types of cancer in the United States from the Surveillance, Epidemiology, and End Results program.
The Summary. A new report shows that cancer cases are shifting from men to women in the United States and from older to younger adults. For the first time, cancer rates in women ages 50 to 64 have ...
A cancer registry is a systematic collection of data about cancer and tumor diseases. The data are collected by Cancer Registrars. Cancer Registrars capture a complete summary of patient history, diagnosis, treatment, and status for every cancer patient in the United States, and other countries. [1]
This is a list of countries by cancer frequency, as measured by the number of new cancer cases per 100,000 population among countries, based on the 2018 GLOBOCAN statistics and including all cancer types (some earlier statistics excluded non-melanoma skin cancer).
The most common cancer among women in the United States is breast cancer (123.7 per 100,000), followed by lung cancer (51.5 per 100,000) and colorectal cancer (33.6 per 100,000), but lung cancer surpasses breast cancer as the leading cause of cancer death among women. [13]
Bayer on Thursday predicted at least $1 billion in 2024 sales for prostate cancer drug Nubeqa, which is playing a bigger role for the drugmaker's growth prospects after the failure of a promising ...